Beike Biotech | Stem Cell Treatment | Stem Cell Research | Embryonic Stem Cells | Stem Cell Therapy | Adult Stem Cell Therapy | Embryonic Stem Cell Therapy | Stem Cell Therapy for Autism | Stem Cell Treatment for Spinal Cord Injury | Stem Cell Technologies | Diabetes | Ataxia Stem Cell Treatment | Cerebral Palsy Treatment | Cell Therapy For Liver Cirrhosis | Multiple Sclerosis Treatment Center | Muscular Dystrophy | Spinal Cord Injury | Spinal Muscular Atrophy (SMA) | Visual Impairment Treatment | Shenzhen, China

Since 2005, Beike has provided partner hospitals with stem cells for the treatment of over 9000 patients. Beike currently provides more than 30 hospitals with umbilical cord, cord blood, and bone marrow-derived stem cells for the treatment of neurological and vascular diseases.

In recent years we have greatly expanded the number of countries represented in our department. We now have members from the US, UK, Italy, Russia, Netherlands, Germany, Romania, Colombia, Brazil, South Africa, North Africa, and the Middle East.

1. Immune system regulation
2. Reducing cell death
3. Stimulation of growth of the patient’s own stem cells
4. Neo-angiogenesis (the growth of blood vessels resulting in increased blood flow to damaged areas)
5. Scar tissue reduction
6. Improving the effective conduction of intercellular electrical signals and transduction

• Ataxia
• Autism
• Cerebral Palsy
• Liver Cirrhosis
• Multiple Sclerosis
• Muscular Dystrophy
• Spinal Cord Injury
• Spinal Muscular Atrophy (SMA)
• Visual Impairment
• and other diseases
  

• Umbilical Cord Blood-Derived Stem Cells (UCBSC)
• Umbilical Cord-Derived Stem Cells (UCMSC)
• Autologous Bone Marrow Stem Cells (BMSC)

How are the stem cells injected?

• Intravenous (IV)
• Lumbar Puncture (LP, Spinal)
• Local Injections (CT-Guided Intraspinal Cord Injection, CT-Guided Stereotactic Intracranial Injection, Intramuscular Injection, Intra-Articular Injection, Retrobulbar Injection)

What are possible treatment locations? (Our Partner Hospitals)

• St. Michael Hospital, Shanghai, China
• Bethune International Peace Hospital, Shijiazhuang, China
• Chengyang People’s Hospital, Qingdao, China
• Guangdong Provincial Hospital, Guangzhou, China

Patient Assistance Fund
December 2011 - January 2012
The end of the year can bring additional expenses that can make seeking treatment difficult. To assist patients who find themselves in this situation, we have created the Patient Assistance Fund to allow all patients arriving during December and January an additional injection during treatment. We sincerely hope this fund will help patients through the additional financial pressure of these two months.

Foreign brands and restaurants, such as McDonalds, KFC, Mercedes, Wal-Mart, Apple Computers, Coke and Pepsi, etc., have been immensely popular for the last ten years. China has a long history of interaction with the West inside of the country’s borders. Shanghai has the French Concession, the British governed Hong Kong until 1997, and Qingdao maintained a large 20th century population of Germans.

This is not to say that China isn’t its own country without its own culture. There are very real cultural and geographic differences that might take patients some time to get accustomed to. Traffic flow is fast and sometimes aggressive, popular public areas can be very crowded, and there are sometimes just as many gray-sky days as there are blue-sky days. And depending on your location, you might get some stares from the locals as you walk by. But for every stare you get on the street, you will also get a smile from the shop person or restaurant waitress. If there is one remark we have heard more than any other from patients, it is how amazingly nice the people are.

Please Click here to request more information from Beike Biotech.

The company was founded with capital from Beijing University, Hong Kong University of Science and Technology, and Shenzhen City Hall. The formation of the company was also supported with grants from the China State National Fund. Since that time, additional capital has been provided by a variety of Chinese venture capital firms.In total, Beike has received over US$6 million in Chinese government grants including a grant for a joint laboratory in Shenzhen with Tsingua University to focus on the study of stem cell reprogramming.

Beike‘s head office is located in Shenzhen but the company also has offices in Beijing, Nanjing, Taizhou, and Qingdao.

The first patient (happening to be diagnosed with ALS) to be treated with Beike processed cells was in 2001. Over 200 patients participated in studies and were treated between 2001 to 2005 in order to determine treatment efficacy for a small number of end-stage and otherwise incurable diseases. Beike was incorporated in July 2005 and has since provided partner hospitals with stem cells for the treatment of over 9000 patients. Beike currently maintains 25 laboratories for both research and cell processing for clinical use and has received over US$6 million in government grants. We even recently had the honor of welcoming Chinese Premier Wen Jiabao for a tour of our Shenzhen facilities in August of 2010.

Our research for future treatments is focused mainly on iPS technology in partnership with various leading scientific groups including Tsinghua Unversity. Beike’s scientists and partners have authored nearly eighty publications in Chinese scientific journals as well as ongoing clinical studies since our first ALS trial program in 2001. We very much welcome cooperation with international partners to help verify the effectiveness of our treatments and protocols and to license other technologies for use throughout our network of twenty seven hospitals.

Beike As A Research Organization

Beike is a dedicated research organization. Our vigor for helping patients extends far beyond simply using stem cells for clinical treatments based on other’s research. It extends into actual scientific research into cell technologies and Beike has been one of the world leaders in this important research. This allows Beike’s treatment protocols and stem cell processing to not only be guided by 3rd party research, but also our own. Beike has almost 50 published peer-reviewed research papers in scientific journals around the world (such as Nature) and has spent tens of millions over the past decade on scientific laboratories and cell research.

Beike As A Treatment Partner

Since 2005, Beike has provided partner hospitals with stem cells for the treatment of over 9000 patients. Beike currently provides more than 30 hospitals with umbilical cord, cord blood, and bone marrow-derived stem cells for the treatment of neurological and vascular diseases. Being the provider, Beike is able to maintain full oversight over cell manufacturing, from the testing of blood products, to cell processing at our laboratories, to delivery of the cells for clinical use. This ensures cell safety and quality. Beike also works closely with our partner hospitals in the evolving of treatment protocols and patient care. Each partner hospital maintains Beike International Department staff to assist patients both with the treatment and with general needs during the hospital stay.

Patient Assistance Fund
December 2011 - January 2012
What is Beike’s Patient Assistance Fund?
The end of the year can bring additional expenses that can make seeking treatment difficult. To assist patients who find themselves in this situation, we have created the Patient Assistance Fund to allow all patients arriving during December and January an additional injection during treatment. We sincerely hope this fund will help patients through the additional financial pressure of these two months.

How do I qualify for this program?
Any patient who is admitted for treatment on any day from December 1, 2011 through January 31, 2012 will receive an additional injection at no additional cost. Patients with any condition -- including those who have already registered for a treatment date in these two months -- are eligible to receive this free injection.

Who will help me schedule my treatment?
Your Beike patient representative can help with the registration process and the scheduling of the treatment and extra injection. Please remember that patients must first be accepted by our International Medical Department before being eligible to register for a treatment date. We hope this Fund will be helpful if you are planning to come during this time. Please contact your patient representative if you have any questions.

Please Click here to request more information from Beike Biotech.

Treatments Offered
A very quick look at the basics of the treatment. Please keep in mind that stem cell treatment is not a cure and has not yet been approved as a treatment by the Food and Drug Administration of the United States. It is a treatment that can help to relieve various symptoms associated with neurological and vascular conditions.

What Type Of Stem Cells Are Used:

• Umbilical Cord Blood-Derived Stem Cells (UCBSC)
• Umbilical Cord-Derived Stem Cells (UCMSC)
• Autologous Bone Marrow Stem Cells (BMSC)

How are the stem cells injected?

• Intravenous (IV)
• Lumbar Puncture (LP, Spinal)
• Local Injections (CT-Guided Intraspinal Cord Injection, CT-Guided Stereotactic Intracranial Injection, Intramuscular Injection, Intra-Articular Injection, Retrobulbar Injection)

What are possible treatment locations?

• St. Michael Hospital, Shanghai, China
• Bethune International Peace Hospital, Shijiazhuang, China
• Chengyang People’s Hospital, Qingdao, China
• Guangdong Provincial Hospital, Guangzhou, China

What is the general treatment length?

• 25 days for 5 stem cell packets
• 30 days for 6 stem cell packets
• 35 days for 7 stem cell packets
• 40 days for 8 stem cell packets

The above are general guidelines and depend upon the doctors’ medical review.

Disease-Specific Information

Below are pages featuring some of the key conditions that have previously received treatment (please note that these are not the only diseases that can be treated and is just a sample).

• Ataxia
• Autism
• Cerebral Palsy
• Liver Cirrhosis
• Multiple Sclerosis
• Muscular Dystrophy
• Spinal Cord Injury
• Spinal Muscular Atrophy (SMA)
• Visual Impairment
• and other diseases, (please contact for details)

What is included in the treatment?

• Stem cell packets and injections
• All necessary testing upon arrival (including any scans as recommended by the attending doctor)
• Rehabilitation, 5-6 days a week (dependent upon injection schedule), PT/OT, massage, electro-wave therapy, acupuncture
• Hospital stay for duration or treatment (rooms include bed for 1-2 caregivers, TV and DVD player, microwave, refrigerator, water cooler, bathroom w/ shower)
• Pickup and transportation from local airport to the hospital
• 25 days for 5 stem cell packets

How is contact continued after returning home?

• Our medical department works with patients to complete a health evaluation upon discharge. Patients then receive notices from the followup coordinator at 1, 3, 6, and 12 months after discharge to complete further health evaluations to assist us in tracking patient health and progress. The followup coordinator is also available to assist with any post-treatment medical inquiries.
• The patient’s representative is available for contact to answer any questions related to the registration process or returning treatments.

 Please Click here to request more information from Beike Biotech.

Key Personnel

CEO and Chairman - Dr. Sean Hu
Dr. Sean Hu, Ph.D; Director of Shenzhen R&D Center of Stemcell Engineering and Technology, Director of Beike Stemcell Research Institute of China Medical City, Director of Shenzhen Beike Cell Engineering Research Institute.

Dr. Sean Hu received his Ph.D from the Department of Biochemistry and Biophysics at Gothenburg University in Sweden in 1998. After spending several years in Sweden he moved to Canada to do his post-doctoral research in the Department of Biochemistry and Molecular Biology at the University of British Columbia. In 2001, he moved back to China, where continuous breakthroughs in the stem cell research field inspired him to support various stem cell research institutions in China. Since then, he has continued to focus his passion and energy towards the progress of stem cell research.

In June 2005, Dr. Sean Hu founded Shenzhen Beike Cell Engineering Research Institute, whose primary mission is to act as a platform for the advanced research of stem cell technology. In 2008, Dr. Sean Hu was listed in the National Annual "Thousand-Person Program" by the Organization Department of the Communist Party of China (CPC) Central Committee for his outstanding achievements in the field of stem cell research.

CSO - Dr. Susan Jiang
Dr. Susan Jiang began her career path as a physician in the field of otorhinolaryngology, specializing in head and neck (ENT-HN) surgery. After receiving her Ph.D. in China, she completed post-doctoral work in the Department of Physiology Biophysics at the University of Arkansas in 2002. In 2005, Dr. Jiang moved to the Pediatrics Department of Stanford University where she investigated the therapeutic potential of stem cells in neo-natal respiratory diseases and developed wound healing models based on stem cell technologies. After nearly three years at Stanford, she became Scientific Director at Escape Therapeutics in the U.S., managing their science team as they developed products based on genetically engineered human stem cells and beta cells for diabetic-related disorders. Dr. Jiang joined Beike as CSO in 2009.

iPS Research Director - Dr. Li Tao
Dr. Tao comes to Beike with over 20 years of research experience in genetics, epigenetics, cell and stem cell biology, molecular biology, cancer biology, and protein chemistry.  He was most recently a senior research scientist at Stanford University's School of Medicine. During his six years at Stanford, he authored or co-authored 22 papers in peer-reviewed journals including Science, Human Molecular Genetics, Cancer Research, and Genomics.  Before Stanford, he earned his Ph.D. at Tokyo University and spent nine years in Japan working on genetics and genetic engineering, publishing articles in 16 international, peer-reviewed, journals.

Please Click here to request more information from Beike Biotech.

Beike Biotechnology Upgrades Its Processing and Cryopreservation Technology to Expedite Advancements in Stem Cell Therapies

Wednesday, 16 March 2011 10:07   

Beike and ThermoGenesis Intend to Establish a "Center of Excellence" Showcase in Taizhou City

TAIZHOU, China, March 16, 2011 /PRNewswire-Asia/ -- Beike Biotechnology Co. Ltd. ("Beike"), China's leading stem cell research and regenerative medicine company, announced an agreement with USA-based ThermoGenesis Corp. to employ new, cutting edge stem cell processing and storage technology across its adult stem cell collection, processing, and archive platform.

Under the arrangement, which underscores Beike's strategic commitment to upgrading its current technology and clinical research capabilities, Beike becomes the first company in the People's Republic of China to secure the rights to the AXP and BioArchive Cord Blood systems. AXP® is a proprietary family of automated devices used for the processing of cord blood; the BioArchive® System is an automated cryogenic device used to archive cord blood stem cell units for transplant.

New Research Demonstrates Safety of Cord-blood-derived Stem Cell Treatments

Friday, 03 September 2010 11:16   

Beike Biotechnology and Medistem, Inc. Report on 114 Patients Treated With Novel Cord Blood Stem Cell Protocol; New Approach Opens Door to Expanded Uses of Cord Blood Stem Cells

SHENZHEN, China, Sept. 2 /PRNewswire-Asia/ -- In a new peer-reviewed article published by the Journal of Translational Medicine, scientists from Beike Biotechnology, China's leading stem cell research and regenerative medicine company, and Medistem, Inc., reported positive safety data in 114 patients who were treated by doctors at Nanshan Affiliated Hospital of Guangdong Medical College (Shenzhen Nanshan Hospital) in Shenzhen using Beike's proprietary cord blood stem cell transplantation protocol.

The peer-reviewed paper is available at http://bit.ly/cBNBYt .

The report aims to serve as an "expanded Phase I" study, with efficacy data to be published in a subsequent paper. It describes biochemical, hematological, immunological, and general safety profiles of patients with neurological diseases who were observed from between one month to four years after treatment. No serious treatment-associated adverse effects were observed.

New Study Demonstrates Improvements in Lupus Patients Receiving Stem Cell Therapies

Tuesday, 08 June 2010 08:25

Lupus study shows promising results using umbilical cord mesenchymal stem cells.

NANJING, Jiangsu, China, June 7, 2010 /PRNewswire-Asia/ -- A new study shows that umbilical cord mesenchymal stem cell transplant (UC-MSCT) may improve symptoms and biochemical values in patients with severe refractory systemic lupus erythematosus (SLE).

In research published online (ahead of print) May 6, 2010 in Arthritis & Rheumatism, lead author and Director of Rheumatology and Immunology at Nanjing University Medical School's renowned Drum Tower Hospital Dr. Lingyun Sun and colleagues report on 16 patients with severe SLE that did not respond to standard treatments. All 16 patients received stem cell transplants. Ten patients completed at least 6 months of follow-up and 2 patients were followed for more than 2 years. There was no treatment-related mortality or other adverse event during or after UC-MSCT, according to the article.

Beike Biotechnology Opens First Chinese Rehabilitation Center in Romania

Wednesday, 21 July 2010 09:53   

New Center Integrates Traditional Chinese, Romanian and Western Therapies

CAMPINA and PRAHOVA, Romania, July 20 /PRNewswire-Asia/ -- Beike Biotechnology Co. Ltd., one of the world's leading biotechnology companies focusing on adult stem cell therapies, opened Romania's first rehabilitation center to use traditional Chinese-style rehabilitation techniques in Campina today.

The new Romanian center is Beike's first stand-alone rehabilitation facility in the world. Physical rehabilitation is a key component of Beike's stem cell therapy protocols which are utilized by leading hospitals throughout China. In conjunction with each one-month stem cell treatment cycle, most patients undergo extensive physical therapy and rehabilitation in an effort to enhance the effects of the stem cells. Chinese patients are able to continue with the rehabilitation after the treatment is completed, but often overseas patients can not find affordable therapy when they return home.

The new 240 square-meter center provides traditional Chinese acupuncture, massage, physical therapy, physiotherapy, electrotherapy and medical exercise-based techniques to help patients with neurological and autoimmune diseases such as ataxia, multiple sclerosis, cardiovascular disease, spinal cord injuries and autoimmune disorders, among others.

Beike Biotech Launches New International Stem Cell Venture

Saturday, 12 June 2010 15:22   

"Beike Holdings Limited", a Strategic Joint Venture With Bangkok-Based SiriCell Technologies, Inc., Will Support the Rapid Clinical Translation of Stem Cell Therapies & Regulatory Approval Outside of China. Alex Moffett, Dr. Sean Hu, and Dato' KK Loh at Beike Holdings Announcement

SHENZHEN, China, June 10 /PRNewswire-Asia/ -- Shenzhen Beike Biotechnology Co. Ltd. ("Beike"), China's leading stem cell research and regenerative medicine company, announced the formation of Beike Holdings Limited ("Beike Holdings") a joint venture with Bangkok-based SiriCell Technologies, Inc. Beike Holdings, which is headquartered in Bangkok, Thailand, will focus primarily on the establishment of new international subsidiaries and the development of collaborative hospital partnerships with Southeast Asia's leading healthcare providers. The joint venture is actively constructing a regional network of world class cGMP stem cell manufacturing labs, distribution centers and storage banks to service and support its hospital training and clinical advisory services.

Beike's stem cells have been shown to be safe and effective in therapies based on direct clinical observation in the hospital setting. Beike Holdings will fund and oversee a series of comprehensive, multi-centered, adaptive Phase 1 and 2 clinical trials to advance the ongoing clinical validations of the safety and efficacy of Beike's stem cell therapies to patients throughout Southeast Asia.

In an effort to expand the availability of Beike's stem cell products for therapeutic applications to hospitals throughout the region, Beike Holdings is establishing subsidiary operations in major Asian urban centers. In the coming weeks Beike Holdings will announce a series of agreements with leading hospitals in Thailand, Malaysia, and the Philippines.

Please Click here to request more information from Beike Biotech.

About China
What was once a country hiding behind a wall and insistent on isolation from the West has now become the second largest economy in the world (behind the US).  Thousands of foreigners now call major Chinese cities home and many central areas of large cities such as Beijing, Qingdao, Shanghai, and Shenzhen now look and feel like their Western equivalents.

Foreign brands and restaurants, such as McDonalds, KFC, Mercedes, Wal-Mart, Apple Computers, Coke and Pepsi, etc., have been immensely popular for the last ten years. China has a long history of interaction with the West inside of the country’s borders. Shanghai has the French Concession, the British governed Hong Kong until 1997, and Qingdao maintained a large 20th century population of Germans.

This is not to say that China isn’t its own country without its own culture. There are very real cultural and geographic differences that might take patients some time to get accustomed to. Traffic flow is fast and sometimes aggressive, popular public areas can be very crowded, and there are sometimes just as many gray-sky days as there are blue-sky days. And depending on your location, you might get some stares from the locals as you walk by. But for every stare you get on the street, you will also get a smile from the shop person or restaurant waitress. If there is one remark we have heard more than any other from patients, it is how amazingly nice the people are.

We fully understand that it is impossible to know exactly what a new place will be like until you actually experience it in person. But we are here to help and provide and details necessary to help you decide if China is a place worth visit to receive treatment.

Please Click here to request more information from Beike Biotech.